Indivior Q2 FY26 GAAP net income rises to $122 million; revenue increases 14% to $343 million YoY

• Indivior posted Q2 2026 net revenue of $ 343 million, up 14% year-over-year; GAAP net income climbed to $ 122 million.
• Adjusted EBITDA more than doubled to $ 186 million; non-GAAP net income rose to $ 142 million.
• SUBLOCADE net revenue increased 21% to $ 253 million; U.S. SUBLOCADE net revenue rose 22% to $ 238 million on 18% dispense unit growth.
• Repurchased 4,664,540 shares for $ 175 million; cash and investments totaled $ 249 million at quarter-end.
• Raised full-year 2026 guidance: net revenue $ 1.3 billion-$ 1.37 billion; adjusted EBITDA $ 700 million-$ 740 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Indivior Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608030631PRIMZONEFULLFEED1001255683) on August 03, 2026, and is solely responsible for the information contained therein.